# A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

> **NCT02999477** · PHASE1 · COMPLETED · sponsor: **Adrienne G. Waks** · enrollment: 32 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Nab-Paclitaxel
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT02999477
- **Lead sponsor:** Adrienne G. Waks
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-23
- **Primary completion:** 2022-11-20
- **Final completion:** 2026-01-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02999477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02999477, "A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02999477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*